Lifevantage Corp Dossier - Source-backed chat

Lifevantage Corp

LFVNNASDAQ

SectorConsumer Staples

IndustryPersonal Care Products

Beta (adjusted)0.83

Intrinsic Value $4.89median of 5 methods · middle span $3-$6based on filings through 31 Mar 2026

Market Price $6.24Price as of 1 Oct 2026

OvervaluedIntrinsic value is 22% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $78.6M

Enterprise Value $58.4M

Shares Outstanding 12.7M diluted

Moat Rating Wide

Next Earnings Date3 Nov 2026

Last ex-dividend1 Jun 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

LifeVantage Corporation is navigating a challenging operational transition characterized by a sharp decline in active accounts and softer-than-expected sales of its flagship MindBody GLP-1 System. While the company maintains a strong, debt-free balance sheet with $12.5 million in cash and continues to return capital to shareholders via dividends and share repurchases, near-term revenue pressure remains significant. The upcoming transition to new CEO Terrence Moorehead in August 2026 represents a potential catalyst for strategic revitalization, but execution risks warrant a cautious, neutral stance in the near term.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets2 analysts · as of 18 Aug 2026

Low · most bearish analyst$5.00

Mean target$7.00

High · most bullish analyst$9.00

Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$5.0020%

The decline in active accounts accelerates, and competitive pressures in the weight loss and wellness space further erode the distributor network. The CEO transition experiences delays or strategic friction, leading to further inventory write-offs and a contraction in operating margins, forcing a reduction in capital return programs.

Base CaseCentral scenario

$7.0050%

Matches the consensus mean

Revenue and active accounts remain under pressure in the near term as the company cycles the initial GLP-1 launch. The interim management team maintains stable operations until Terrence Moorehead takes over in August 2026. Gross margins remain robust near 79%, and the company continues to pay its quarterly dividend, keeping the stock range-bound.

Bull CaseUpside scenario

$9.0030%

The new CEO successfully stabilizes the core activation portfolio, accelerates the integration of LoveBiome, and expands international markets (such as Portugal). Cost-saving initiatives and high gross margins (around 79%) drive a rapid recovery in operating leverage, leading to a strong rebound in EPS and valuation multiples.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong balance sheet with $12.5 million in cash and zero debt as of March 31, 2026.
High gross margin profile consistently maintained around 79% to 81%.
Commitment to shareholder returns, including a recent 11.1% increase in the quarterly dividend to $0.05 per share.
Incoming CEO Terrence Moorehead has a proven track record of driving growth and scaling global health and wellness brands.

Key Investment Risks

Significant top-line pressure, with Q3 FY2026 revenue declining 25.2% year-over-year.
Contraction of the active customer and consultant base, with active accounts down 22.1% year-over-year to 109,000.
Challenging competitive dynamics in the weight loss market impacting the MindBody GLP-1 System.
Leadership transition execution risk during the interim period before the new CEO takes office in August 2026.

Thesis Invalidation Triggers

Failure of the new CEO to assume office on August 5, 2026, or sudden changes to the transition plan.
A drop in gross margins below 75% due to severe inventory obsolescence or supply chain inflation.
A material reduction or suspension of the quarterly dividend program.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.